Home  |  Contact

Cellosaurus JK-6L (CVCL_0C41)

[Text version]
Cell line name JK-6L
Synonyms JK6L; JK-6 IL6-independent
Accession CVCL_0C41
Resource Identification Initiative To cite this cell line use: JK-6L (RRID:CVCL_0C41)
Comments Characteristics: Produces IgG kappa.
Characteristics: Compared to the parent cell line, it is no longer IL6 dependent.
Doubling time: ~48 hours (DSMZ=ACC-860).
Omics: Array-based CGH.
Omics: Transcriptome analysis by RNAseq.
Caution: Indicated as JK-6 in DSMZ, but the original JK-6 was IL-dependent and the IL-6 independent subline was called JK-6L (PubMed=19621390).
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (DSMZ=ACC-860).
  • Mutation; HGNC; 7795; NFKB2; Simple; p.Arg725Glufs*18 (c.2171delC); Zygosity=Homozygous (PubMed=17692805).
  • Mutation; HGNC; 7989; NRAS; Simple; p.Tyr64Asp (c.190T>G); dbSNP=rs752508313; Zygosity=Unspecified (DSMZ=ACC-860).
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_M534 (JK-6)
Children:
CVCL_A5DY (JK-6L.31H)CVCL_A5DZ (JK-6L.39L)
Sex of cell Male
Age at sampling 75Y
Category Cancer cell line
STR profile Source(s): DSMZ

Markers:
AmelogeninX,Y
CSF1PO12
D2S133816,17
D3S135816,17
D5S81813
D7S8208,12
D8S117910,14
D13S31711,12
D16S53911
D18S5112,13,16
D19S43313,14
D21S1131.2,32
FGA19,23
Penta D12
Penta E12
TH019.3
TPOX11
vWA15,17

Run an STR similarity search on this cell line
Web pages https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
Publications

PubMed=17308121; DOI=10.1158/0008-5472.CAN-06-2258
Meister S., Schubert U., Neubert K., Herrmann K., Burger R., Gramatzki M., Hahn S., Schreiber S., Wilhelm S., Herrmann M., Jack H.-M., Voll R.E.
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Cancer Res. 67:1783-1792(2007)

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 12:131-144(2007)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=19621390; DOI=10.1002/ijc.24758
Guenther A., Gordon S., Tiemann M., Burger R., Bakker F., Green J.R., Baum W., Roelofs A.J., Rogers M.J., Gramatzki M.
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Int. J. Cancer 126:239-246(2010)

CLPUB00604
Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017), University of Toronto, Canada

PubMed=32123307; DOI=10.1038/s41375-020-0785-1
Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B., Sirota M., Wiita A.P.
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Leukemia 34:2754-2765(2020)

Cross-references
Cell line collections (Providers) DSMZ; ACC-860
Cell line databases/resources cancercelllines; CVCL_0C41
DSMZCellDive; ACC-860
Encyclopedic resources Wikidata; Q54898960
Polymorphism and mutation databases Cosmic; 2081386
Entry history
Entry creation10-Apr-2015
Last entry update30-Jan-2024
Version number13